EPS for Regeneron Pharmaceuticals (REGN) Expected At $3.79; Wfg Advisors LP Raised Facebook (FB) Stake

October 12, 2017 - By Hazel Jackson

Wfg Advisors Lp increased Facebook Inc (FB) stake by 20.36% reported in 2017Q2 SEC filing. Wfg Advisors Lp acquired 2,187 shares as Facebook Inc (FB)’s stock rose 10.88%. The Wfg Advisors Lp holds 12,929 shares with $1.95M value, up from 10,742 last quarter. Facebook Inc now has $501.12B valuation. The stock decreased 0.11% or $0.19 during the last trading session, reaching $172.55. About 10.33 million shares traded. Facebook Inc (NASDAQ:FB) has risen 26.75% since October 12, 2016 and is uptrending. It has outperformed by 10.05% the S&P500.

Analysts expect Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to report $3.79 EPS on November, 3.They anticipate $1.38 EPS change or 57.26% from last quarter’s $2.41 EPS. REGN’s profit would be $406.08 million giving it 29.50 P/E if the $3.79 EPS is correct. After having $3.88 EPS previously, Regeneron Pharmaceuticals Inc’s analysts see -2.32% EPS growth. The stock decreased 1.28% or $5.82 during the last trading session, reaching $447.15. About 697,834 shares traded. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has risen 17.40% since October 12, 2016 and is uptrending. It has outperformed by 0.70% the S&P500.

Since April 28, 2017, it had 0 insider buys, and 25 selling transactions for $796.22 million activity. On Tuesday, May 2 Stretch Colin sold $114,881 worth of Facebook Inc (NASDAQ:FB) or 750 shares. Shares for $2.45M were sold by Cox Christopher K. 279,533 shares were sold by Zuckerberg Mark, worth $42.50M on Friday, May 26. $5.71 million worth of Facebook Inc (NASDAQ:FB) was sold by Schroepfer Michael Todd on Tuesday, June 13. $25.14M worth of Facebook Inc (NASDAQ:FB) was sold by Sandberg Sheryl. 594,246 shares valued at $88.97M were sold by Koum Jan on Monday, May 15. Another trade for 209 shares valued at $30,236 was made by Desmond-Hellmann Susan on Thursday, May 18.

Investors sentiment increased to 1.4 in Q2 2017. Its up 0.05, from 1.35 in 2017Q1. It improved, as 48 investors sold FB shares while 553 reduced holdings. 159 funds opened positions while 684 raised stakes. 1.62 billion shares or 0.41% less from 1.63 billion shares in 2017Q1 were reported. Adams Diversified Equity Fund Inc holds 303,300 shares or 2.58% of its portfolio. Middleton & Commerce Incorporated Ma reported 79,803 shares or 2.57% of all its holdings. Cohen Klingenstein Ltd Liability Company holds 0.66% or 28,000 shares in its portfolio. The New York-based Investec Asset Mgmt North America has invested 0.62% in Facebook Inc (NASDAQ:FB). Pictet Retail Bank owns 2.68% invested in Facebook Inc (NASDAQ:FB) for 56,250 shares. Motley Fool Wealth Ltd Liability Company stated it has 358,512 shares or 4.91% of all its holdings. The Wisconsin-based Jacobus Wealth Inc has invested 0.07% in Facebook Inc (NASDAQ:FB). Monetary Inc accumulated 29,975 shares. Zeke Capital Advisors Llc invested 0.73% in Facebook Inc (NASDAQ:FB). California-based Diligent Limited Liability Company has invested 0.36% in Facebook Inc (NASDAQ:FB). Seatown Holding Pte Ltd reported 4.52% of its portfolio in Facebook Inc (NASDAQ:FB). World Asset Mgmt holds 1.19% or 227,813 shares in its portfolio. Massachusetts Financial Company Ma holds 0.88% or 13.12M shares. Cullinan Associates holds 2.6% of its portfolio in Facebook Inc (NASDAQ:FB) for 221,400 shares. Grand Jean owns 111,234 shares for 6.41% of their portfolio.

Wfg Advisors Lp decreased Johnson & Johnson (NYSE:JNJ) stake by 2,724 shares to 24,745 valued at $3.27 million in 2017Q2. It also reduced Hsbc Hldgs Plc (NYSE:HSBC) stake by 15,010 shares and now owns 195 shares. Vanguard Bd Index Fd Inc (BND) was reduced too.

Among 52 analysts covering Facebook (NASDAQ:FB), 48 have Buy rating, 2 Sell and 2 Hold. Therefore 92% are positive. Facebook had 182 analyst reports since July 21, 2015 according to SRatingsIntel. Monness Crespi & Hardt maintained the stock with “Buy” rating in Thursday, November 5 report. The company was upgraded on Tuesday, July 21 by Bank of America. The stock of Facebook Inc (NASDAQ:FB) has “Sell” rating given on Friday, October 30 by Jyske Bank. As per Thursday, November 3, the company rating was maintained by Mizuho. The rating was maintained by RBC Capital Markets with “Buy” on Wednesday, September 6. The rating was maintained by William Blair with “Buy” on Thursday, July 20. The company was maintained on Thursday, April 28 by Barclays Capital. On Monday, September 11 the stock rating was maintained by BMO Capital Markets with “Hold”. The company was maintained on Thursday, April 28 by Nomura. BMO Capital Markets maintained the stock with “Market Perform” rating in Thursday, November 3 report.

Since May 12, 2017, it had 1 buy, and 7 sales for $42.75 million activity. The insider BROWN MICHAEL S sold $1.35M. The insider STAHL NEIL sold $4.01M. $9.90M worth of stock was sold by Terifay Robert J on Thursday, June 15. Sanofi bought $65.06 million worth of stock. The insider VAGELOS P ROY sold 9,295 shares worth $4.26M. Another trade for 1,000 shares valued at $482,550 was sold by GOLDSTEIN JOSEPH L.

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical firm that discovers, invents, develops, makes and commercializes medicines for the treatment of serious medical conditions. The company has market cap of $47.91 billion. The Firm commercializes medicines for eye diseases, high low-density lipoprotein cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. It has a 44.88 P/E ratio. The Company’s marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.

Investors sentiment increased to 1.38 in Q2 2017. Its up 0.12, from 1.26 in 2017Q1. It increased, as 42 investors sold Regeneron Pharmaceuticals Inc shares while 157 reduced holdings. 84 funds opened positions while 190 raised stakes. 71.53 million shares or 1.38% more from 70.55 million shares in 2017Q1 were reported. Winslow Cap Mgmt Limited Liability Co accumulated 19 shares. Deutsche Savings Bank Ag holds 0.08% or 217,965 shares in its portfolio. Virtus Inv Advisers has invested 0.02% of its portfolio in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). National Bank Of Nova Scotia holds 0.04% of its portfolio in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 17,187 shares. Whittier Trust owns 35 shares. Kentucky Retirement Systems accumulated 4,885 shares or 0.18% of the stock. Kelly Lawrence W Assoc Inc Ca owns 25,220 shares for 2.45% of their portfolio. The New York-based Oppenheimer Asset Mgmt has invested 0.14% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Next Grp Inc Incorporated reported 835 shares. Alpine Woods Investors Ltd Company holds 0.03% or 1,000 shares. Ameriprise Finance accumulated 217,208 shares or 0.05% of the stock. Lord Abbett And Com Ltd Com owns 105,736 shares for 0.15% of their portfolio. Carroll Financial Assocs owns 82 shares. Overbrook Management Corp, New York-based fund reported 1,258 shares. Commercial Bank Of Montreal Can has 42,414 shares for 0.02% of their portfolio.

Among 28 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 13 have Buy rating, 1 Sell and 14 Hold. Therefore 46% are positive. Regeneron Pharmaceuticals Inc. had 89 analyst reports since July 28, 2015 according to SRatingsIntel. The company was initiated on Wednesday, August 16 by Evercore. The rating was initiated by Bernstein with “Outperform” on Wednesday, June 29. As per Friday, December 16, the company rating was upgraded by BTIG Research. The firm has “Hold” rating by BMO Capital Markets given on Thursday, August 3. Credit Suisse maintained Regeneron Pharmaceuticals Inc (NASDAQ:REGN) rating on Monday, September 11. Credit Suisse has “Buy” rating and $485.0 target. Robert W. Baird maintained it with “Sell” rating and $408.0 target in Thursday, September 7 report. The stock has “Buy” rating by Piper Jaffray on Thursday, September 28. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned “Outperform” rating by RBC Capital Markets on Friday, January 6. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned “Hold” rating by Canaccord Genuity on Wednesday, January 27. The rating was maintained by Cowen & Co with “Hold” on Monday, July 31.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>